Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma
- 31 August 2006
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Journal of Neuro-Oncology
- Vol. 82 (1), 81-83
- https://doi.org/10.1007/s11060-006-9241-y
Abstract
Concurrent temozolomide (TMZ) and radiotherapy is the new standard of care for patients with newly diagnosed glioblastoma. In 51 consecutive patients treated according to this regimen, 7 patients (14%) manifested surgically confirmed early necrosis without evidence of recurrent tumor. This observation suggests that daily TMZ may represent a potent radiosensitizing regimen.Keywords
This publication has 7 references indexed in Scilit:
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Immediate post-radiotherapy changes in malignant glioma can mimic tumor progressionNeurology, 2004
- Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomasCancer, 2003
- Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant TemozolomideJournal of Clinical Oncology, 2002
- Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trialsThe Lancet, 2002
- Brain TumorsNew England Journal of Medicine, 2001
- Recursive Partitioning Analysis of Prognostic Factors in Three Radiation Therapy Oncology Group Malignant Glioma TrialsJNCI Journal of the National Cancer Institute, 1993